Murdoch University’s menopause project will combine cognitive assessments, blood biomarkers and health information. Here is what the announcement means.
On 29 September 2026, Murdoch University announced the WA Women’s Brain Health project to investigate how menopause and related factors shape brain health before, during and after the transition.
According to the university’s announcement, the project is funded by a Future Health Research and Innovation Fund grant. Associate Professor Belinda Brown of Murdoch’s Centre for Healthy Ageing leads the work.
The other named researchers are:
The university describes a team that includes three emerging postdoctoral researchers and a PhD candidate. Its expertise spans women’s health and cognitive aging alongside exercise and lifestyle research. Metabolomics and phenotyping are also among the specialties listed in the announcement.
The researchers come from Murdoch’s Centre for Healthy Ageing, School of Allied Health and Centre for Computational and Systems Medicine. Bringing these fields together is part of the project’s approach to studying brain health across different stages of women’s lives.
The central question reaches beyond menopause itself. The researchers want to understand how this transition fits into a wider picture that includes health and lifestyle through midlife and later life.
Murdoch says the team plans to bring together cognitive assessments, blood biomarkers and detailed information about menopause. Lifestyle and health information will also form part of the research.
These sources of information have different roles in the planned investigation. Cognitive assessments will sit alongside blood measurements rather than being examined in isolation. Information about menopause and wider health will add context to those measurements.
That combination is the project’s defining approach. Instead of presenting menopause as the sole explanation for later-life brain health, the plan places it among several factors for investigation.
Brown said the aim is to help women make informed choices about brain health. She also expressed the hope that the findings could inform the development of future interventions. That is the intended direction of the research rather than an announced clinical outcome.
Other research provides context for this interest in the connection between menopause and later-life cognition. Those studies examine different measures and come from outside the WA Women’s Brain Health project.
According to the University of California, San Francisco, a separate study reported in Nature Medicine identified 16 blood molecules whose levels changed across the menopause transition.
The research included an analysis of almost 12,000 women in their 60s and early 70s drawn from four previous studies. Higher levels of the identified molecules were associated with worse memory and a 15% higher risk of Alzheimer’s disease.
A separate report from Yahoo described a study of 2,603 older women followed for up to 18 years. Earlier menopause was associated with faster cognitive decline, including episodic memory decline. It was also associated with earlier Alzheimer’s diagnosis.
Together, these reports show why researchers are asking questions about the relationship between midlife changes and later cognitive health. One examines menopause-related blood molecules. The other examines menopause timing in relation to outcomes over time.
Murdoch’s planned work brings its own combination of cognitive assessments and biological measurements to this broader field. Its inclusion of detailed health and lifestyle information is another part of the proposed investigation.
For women over 60, the announcement directs attention to connections between midlife and later life. The project explicitly includes brain health after menopause rather than focusing only on the transition itself.
That matters to how the story should be read. A woman reading about this work years after menopause is still within the life stages the project aims to understand. The research question is broader than what happens at the time of the transition.
For researchers, the announcement sets out an approach that combines several types of evidence. The practical interest lies in how these measures will be examined together and what the eventual findings add to existing research.
For clinicians and patients, the useful task today is to distinguish the project’s questions from decisions about an individual’s care. Questions about personal memory changes or treatment belong in a discussion with a qualified healthcare professional.
Readers following other research on women’s brain aging can keep each project’s purpose and methods separate. A funding announcement answers a different question from a report of completed findings.
When future coverage appears, useful details to look for include:
These are reading questions rather than personal health instructions. They help keep attention on what the researchers actually measured instead of what a headline might suggest.
The Murdoch announcement describes a research plan. It does not report completed trial results or demonstrate that an intervention protects cognition. Brown’s hope for future interventions should therefore be read as a research ambition.
The outside studies also have a specific evidence boundary. Their findings are observational associations. They do not establish that menopause causes Alzheimer’s disease or that menopause timing itself causes cognitive decline.
The reported 15% higher risk applies to an association involving levels of the identified molecules in older women. It should not be rewritten as a claim that menopause raises every woman’s Alzheimer’s risk by that amount.
Nor do these reports establish a personal forecast. Neither menopause history nor the blood molecules described here have been shown by these sources to determine an individual woman’s cognitive future. The announcement does not establish a new diagnostic tool for routine care.
The practical response is to treat the proposed biomarkers as research leads. There is no basis in this announcement for choosing a treatment or changing a health routine because of a presumed menopause-related dementia risk.
For readers assessing claims about protecting cognitive health, the distinction is straightforward: a promising question is a reason to follow the research. A personal medical decision requires evidence that addresses that decision and guidance from qualified care.
The significance of the WA Women’s Brain Health project lies in its scope. Murdoch’s team plans to examine menopause alongside cognitive measures and biological information while also taking account of lifestyle and health.
That approach gives the research a broader purpose than identifying a single marker. It asks how several parts of women’s health relate to brain health from midlife into later life.
The long-term value will depend on what the project finds. For now, the announcement marks a defined research effort toward a fuller account of women’s cognitive aging. It is a development worth following without turning its goals into conclusions.
A menopause project can sound like a finished answer before findings exist, so FitBrainLab separates the research question from the evidence available. Its reporting helps adults 60+ judge early brain-health claims by explaining complex research clearly and keeping open questions visible without alarm or medical promises.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
